Drug profile

The FDA adverse-event record for Tylosin Phosphate

227 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Tylosin Phosphate. See the species affected, top reactions, and outcomes below.

227
adverse-event reports
59.5%
death-coded share
Cattle
most-reported species
113
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
227
Total Reports
135
Deaths Reported
59.5%
Death Rate

Active Ingredients

Tylosin Phosphate

Administration Routes

OralUnknownOtherCutaneousRespiratory (Inhalation)

Species Affected

Cattle 149
Pig 32
Unknown 17
Dog 15
Chicken 9
Human 4
Horse 1

Most Affected Breeds

Cattle (unknown) 47
Crossbred Bovine/Cattle 40
Cattle (other) 25
Pig (unknown) 24
Unknown 21
Holstein-Friesian also known as Holstein 11
Aberdeen Angus 11
Mixed (Cattle) 10
Chicken (unknown) 5
Cornish Cobb 3

Most Reported Reactions

Death 113
Pneumonia 54
Lameness 53
Respiratory tract disorder NOS 37
Unclassifiable adverse event 33
Bloated 30
Lack of efficacy - NOS 27
Ruminal bloat 26
Behavioural disorder NOS 22
Peritonitis 21
Lack of efficacy (bacteria) - NOS 20
Found dead 19

Outcome Breakdown

Died
133 (42.2%)
Outcome Unknown
129 (41.0%)
Recovered/Normal
27 (8.6%)
Euthanized
18 (5.7%)
Ongoing
6 (1.9%)
Recovered with Sequela
2 (0.6%)

Tylosin Phosphate Adverse Event Insights

227 reports name Tylosin Phosphate; 135 recorded a death outcome (59.5% of reported events, not a population-level mortality rate). Active ingredient: Tylosin Phosphate. Administration routes: Oral, Unknown, Other, Cutaneous.

By species: Cattle (149 reports), Pig (32 reports), Unknown (17 reports). By breed: Cattle (unknown) (47), Crossbred Bovine/Cattle (40), Cattle (other) (25).

Leading clinical signs: Death (113), Pneumonia (54), Lameness (53), Respiratory tract disorder NOS (37). Outcome, 315 coded reports: Died leads at 42.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.